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populations. Studies in subjects of European ancestry have indicated that HLA-B*1502 is not present in CBZ-SJS patients of European descent [10, 11] . This is not surprising considering the decreasing frequency of the HLA-B*1502 allele from a high frequency of 6% in Asia to virtually absent in Europe [12] .
A 2006 study by Hung and colleagues reported an association between CBZ-induced MPE with HLA-A*3101 among patients of Han Chinese descent [13] . Using a genomewide approach, we identified HLA-A*3101 as a clinically relevant predictor for the full spectrum of CBZ-induced hypersensitivity reactions in Europeans, while a separate study by Ozeki and colleagues reported a significant association with HLA-A*3101 and CBZ-induced cADRs in a Japanese population [14, 15] . The relationship between HLA-A*3101 and CBZ-induced HSS has now also been reported in patients of Korean descent [16] .
Here we set out to investigate whether HLA-A*3101 or any other common genetic variant identified through genome-wide association studies (GWAS) may act as a predisposing factor for two of the other common AEDs known to cause cADRs, namely LTG and PHT.
Materials & methods
n Case subjects We obtained approval for this study from the local research ethics committees of each site. Written, informed consent was obtained from all subjects prior to participation. Patients were recruited through centers affiliated with the EPIGEN Consortium; namely Duke University (NC, USA), University College London (London, UK), Université Libre de Bruxelles (Brussels, Belgium) and the Royal College of Surgeons in Ireland with Beaumont Hospital (Dublin, Ireland).
All patients were of European ancestry as determined by self-report and genetic-marker ana lysis. Cases were separated according to the causal drug and then phenotyped into distinct hypersensitivity states of MPE, HSS and SJS based on the extent and severity of their ADR and using disease criteria, as previously reported [14] . In total, there were 46 ADR cases relating to LTG, of which 42 were MPE cases, three were HSS and one was SJS. Of the 44 PHTinduced ADR cases, 40 were MPE cases and four were HSS cases. There were four patients who experienced MPE with both drugs on separate occasions and were thus included in each set of analyses. Given the low numbers of HSS and SJS patients and the evidence that a common marker may exist for all phenotypes (as evidence would suggest for HLA-A*3101 and CBZ-induced cADRs) we analyzed all cases together as drug-specific cADR groups.
n Control subjects The control group consisted of a homogeneous subgroup of 1296 subjects from the 1958 British birth cohort that were selected by principal component ana lysis of GWAS. Controls were unscreened for AED-related ADRs.
n Genome-wide ana lysis Genome-wide data across >600,000 SNPs were available for 34 LTG and 42 PHT cases and all 1296 population control subjects. Genotyping for all cases was performed with the Illumina ® Human610-610K Quad platform at the Duke University Center for Human Genome Variation (NC, USA). We removed subjects with a genotyping failure rate below 95%, SNPs with low minor allele frequency (<2%), those failing the Hardy-Weinberg equilibrium and any that had missing genotype information in >10% of all subjects. n Imputation of HLA alleles We imputed classic HLA alleles for all cases and controls using MACH 1.0 [17] . This method has been validated as an accurate method for imputing HLA subtypes in our cohort as described previously [14] . The HLA-typed 1958 British birth cohort constituted the reference population for imputation. For those samples for which GWAS data were not available we used PCR with sequence-specific primers to determine the presence of HLA-A*3101. The PCR conditions were as follows: the forward primer sequence was 5´-GATAGAGCAGGAGAGGCCT-3´, r e v e r s e p r i m e r s e q u e n c e w a s 5´-AGCGCAGGTCCTCGTTCAA-3´ and the cycling parameters were 95°C for 3 min, five cycles of 95°C for 15 s, 70°C for 15 s and 72°C for 30 s, two cycles of 95°C for 15 s, 65°C for 15 s and 72°C for 30 s, four cycles of 95°C for 15 s, 55°C for 1 min and 72°C for 2 min, finally 72°C for 7 min.
n Statistical analysis Statistical analyses were performed using PLINK (version 1.05) [18] and EIGENSTR AT [19] software packages. For the GWAS, we applied logistic regression (using an additive model) to each of the cADR case groups in turn versus the 1958 British birth cohort controls. We adjusted for population stratification by including significant principal components (generated using EIGENSTR AT) as covariates in the logistic-regression model and used a p-value of less than 5.0 × 10 -8 as a threshold for genomewide significance. Supplementary Figure S1 (see online, www.futuremedicine.com/doi/suppl/10.2217/ PGS.11.165) for a plot of the first and second principal components between cases and controls. Post-GWAS annotation ana lysis was performed with WGAViewer [20] . We calculated study power using the program Power for Genetic Association Analyses [21] . We estimated the relative risk (RR) required for 80% power to detect an allelic association (under an additive disease model) with the following parameters: a prevalence of 10% of the ADR in the population, a minor allele frequency of 5%, an experimentwide a level of 0.05 and the assumption that a genetic marker is causal or in complete linkage with the causal variant.
Results
n HLA-A*3101 as a predictor of LTGand PHT-induced cADRs table 1 illustrates the results of HLA-A*3101 genotyping in LTG-and PHT-induced cADR cases and population controls. The allele does not appear to be enriched in any of the cADR patient groups. For each of the analyses considered, our power calculations indicate that we had reasonable power to detect effect sizes of clinical relevance (RR >2).
n GWAS results
We next conducted a GWAS for each of the drug-specific cADR groups as well as a total combined case cohort. The results of the logistic regression analyses are depicted as Manhattan and quantile-quantile plots in The ten most significant markers from the logistic regression analyses are listed in Supplementary tableS S1-S3. We did not detect any variants satisfying our threshold for genomewide significance (p-value of 5.0 × 10 -8 ), nor did we observe any significant deviations from the expected distribution in quantile-quantile plots (results shown in FigureS 1 & 2) . From power calculations (Figure 3) we estimated that we had 80% power to detect a variant with a minor allele frequency >10% and a RR >2.5 when considering all cases together. We feel this RR is within the realm of clinical relevance.
Discussion
The results presented here suggest that HLA-A*3101 is not a clinically relevant predictor of cADRs caused by LTG and PHT in populations of European descent.
It has been shown in previous studies by ourselves and others that HLA-A*3101 is a strong predictor for the clinical spectrum of CBZ-induced hypersensitivity and we reported an odds ratio of 8.33 for CBZ-induced MPE for a population of European descent, while the corresponding value for a population of Japanese descent was 10.8 [15] .
We calculated that the current study had 80% power to detect a RR of 3.27 for cADRs based on a frequency of 5% for HLA-A*3101, which gives this study ample power to detect an effect size similar to that reported previously for CBZinduced MPE. If HLA-A*3101 is a predictor for either LTG-or PHT-induced cADRs, we were well powered to detect it. Of the 44 cases of PHT-induced cADRs, only two were positive for HLA-A*3101. Similarly, only two of the 46 cases of LTG-induced cADRs were positive for the allele. Incidentally, one of the subjects positive for HLA-A*3101 in the LTG case group had a historical report of a rash with CBZ.
Although we included HSS and SJS, the overwhelming majority of cases were of the MPE type. Given the small number of HSS and SJS cases, we pooled all cases into a single group of hypersensitivity ADR cases per drug for a better powered genome-wide ana lysis. We chose to analyze all cases together as cADR groups as we did not have enough subjects to run a powered GWAS for HSS or SJS alone. The GWAS results remain negative when the HSS and SJS cases are removed. Further studies of PHT-and LTGinduced HSS and SJS in larger patient cohorts is warranted, especially given that the genetic predictors (e.g., HLA-B*1502) can be selective for a given hypersensitivity reaction [5, 13, 22] , and the effect size correlates with the severity of the phenotype across the hypersensitivity spectrum (as appears to be the case for HLA-A*3101 and CBZ [14, 16] ).
Our GWAS results are not suggestive of a common, clinically relevant predictor of LTG-or PHT-induced cADRs in a European population. None of the variants tested satisfied the GWAS significance threshold, nor was there any clear biological candidate from within the pool of the most significant SNPs (Supplementary tableS S1-S3). Our study was powered to detect a variant of minor allele frequency >10% carrying a clinically relevant genetic effect (RR > 2.5). We recognize that sample size is a major limitation of our study. This has limited our ana lysis to effect sizes in the realm of clinical relevance (for cADRs) and has prevented us from studying SJS/TEN specifically. We also cannot rule out genetic variants conveying smaller effects (RR <2.5) or rare variants of small or large effect, which were not captured by our GWAS chip.
With the increased availability of wholeexome and whole-genome sequencing, it should become possible and more affordable to identify rare variants not captured through GWAS. Discovering these genetic markers would further the understanding of the functional role of HLA in drug response, as well as helping clinicians screen patients susceptible to these ADRs. This study mainly focused on patients With this knowledge we investigated whether HLA-A*3101 or any other common genetic marker was associated with lamotrigine-(LTG) or PHT-induced cADRs.
Results
There was no association between HLA-A*3101 and LTG-or PHT-induced cADRs. We did not find a significant common genetic variant from our genome-wide analyses.
Conclusion
We have shown that the association with HLA-A*3101 does not extend to LTG-or PHT-induced cADRs. We also did not detect any other significant common variants of association with LTG-or PHT-induced cADRs from genome-wide association studies. HLA-A*3101 thus appears to be a specific marker for CBZ-induced cADRs.
with the less severe MPE hypersensitivity reaction; however, there is a clear motivation to investigate whether HLA-A*3101 extends itself as a genetic marker for HSS and SJS/TEN caused by LTG and PHT.
HLA-A*3101 does not appear to be a genetic marker for LTG-and PHT-induced MPE reactions in Europeans. The predictive application of HLA-A*3101 as a clinically relevant genetic marker for cADRs in Europeans appears to be specific to CBZ.
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